Disc Medicine’s FDA Meeting Just Reset the Bitopertin Timeline: What the Street Should Actually Be Watching
After a Feb 2026 CRL rejection, Disc Medicine secured FDA alignment on a Phase 3 pathway for bitopertin in...
erythropoietic protoporphyria
After a Feb 2026 CRL rejection, Disc Medicine secured FDA alignment on a Phase 3 pathway for bitopertin in...